We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
What's new
This page lists items that we have published for the first time or updated in the last 7, 30 or 60 days. Use the filters to narrow results by audience, product type, content type or topic.
You can also stay informed by:
- subscribing to our updates to receive same-day notification emails on safety information, scheduling updates or media releases.
- checking for open consultations.
- joining any upcoming events.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (2)
- Breast implant hub (1)
- Committees and advisory bodies (9)
- Compliance and enforcement (3)
- COVID-19 (3)
- Labelling and packaging (3)
- Legislation (4)
- Manufacturing (2)
- Medicinal cannabis hub (1)
- Safety monitoring and information (15)
- Scheduling (national classification system) (3)
- Shortages and supply disruptions (7)
- Sunscreens (4)
- Vaping hub (5)
What's new
83 result(s) found, displaying 51 to 75
-
Meeting statementsMedical device reforms: Consumer Working Group meeting statement, Meeting 17, 22 August 2025
-
ServiceAs a medical practitioner, you can apply to access an unapproved therapeutic good for a class of patients with the same condition.
-
PageFour pathways medical professionals can use to give patients unapproved medicinal cannabis.
-
Bondi Sands Zinc Mineral Broad Spectrum UVA & UVB Protection Sunscreen SPF 50+ Face and Body Lotions
Market actionsBondi Sands Pty Ltd is recalling five batches of sunscreen due to the potential for the lotions to become separated. -
PageThis page contains a list of therapeutic vaping goods, for use in smoking cessation or the management of nicotine dependence, that can be legally supplied in Australia. Healthcare practitioners can use this list when prescribing and supplying unapproved therapeutic vaping goods as they have been notified as complying with applicable standards.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsThe 87th meeting of the Advisory Committee on Medical Devices (ACMD) was held on 9 October 2025.
-
CommitteeInformation on the role and membership of ACMD and proposed meeting dates.
-
CommitteeInformation on the role and membership of ACM and proposed meeting dates.
-
DatasetSearch companion diagnostics (CDx) we have approved for supply in Australia.
-
PageA list of approved COVID-19 tests included in the ARTG for supply in Australia.
-
PageThe TGA has selected a list of medicines that have a history of shortage, are clinically important and impact on public health.
-
-
PageTo enable timely distribution of COVID-19 vaccines, international labels are being used during the initial global rollout, including in Australia.
-
Regulatory decision noticesThis instrument is made under Schedule 5A to the Therapeutic Goods Regulations 1990 and Schedule 4 to the Therapeutic Goods (Medical Devices) Regulations 2002.
-
-
Australian public assessment report (AusPar)Afqlir; Enzeevu (aflibercept) 2 mg is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (wet AMD), CRVO, BRVO, DMEmyopic and CNV.
-
PageWe ensure there is an independent quality assessment for every batch of vaccine supplied in Australia.
-
News articlesThe International Medical Device Regulators Forum (IMDRF) Software as a Medical Device (SaMD) Working Group has published the draft Essential Principles and Content of Predetermined Change Control Plans document for public consultation.
-
PageFind out how therapeutic goods legislation applies to social media posts, comments, hashtags, and paid promotions. Includes practical resources for businesses, influencers and consumers.
-
Australian public assessment report (AusPar)Eydenzelt (aflibercept) has been approved for the treatment in adults of visual impairment due to myopic choroidal neovascularisation.
-
Australian public assessment report (AusPar)Pluvicto (lutetium (177Lu) vipivotide tetraxetan) is approved for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
-
FormsThis form allows sponsors of notified therapeutic vaping goods, which includes therapeutic vaping kits, to provide information to the TGA about the supply of those goods during a specified period, upon formal request by the Secretary or their delegate.
-
PageAll medicines included in the Australian Register of Therapeutic Goods (ARTG) must include the relevant AUST number on the label.
-
PageWe are part of the Health Products Regulation Group (HPRG) in the Australian Government Department of Health, Disability and Ageing.